Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR)   JANUARY 2015 , Volume 9 , Number 1; Page(s) 26 To 32.
 
Paper: 

OUTCOME OF RAPAMYCIN THERAPY FOR POST- TRANSPLANT- LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION: CASE SERIES

 
 
Author(s):  ASHRAFI FARZANEH, SHAHIDI SHAHRZAD, EBRAHIMI ZEINAB*, MORTAZAVI MOJGAN
 
* ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN
 
Abstract: 

Background: Post-transplant lymphoproliferative disorders (PTLD) are a complication of chronic immunosuppressive therapy in solid organ transplantation with a high mortality rate. Alternative treatments such as rapamycin have been explored.
Methods: A detailed retrospective analysis was performed according to data collected from 13 patients with PTLD. At the time of PTLD diagnosis, immunosuppressive therapy was decreased and rapamycin administered. Overall survival, disease-free survival of patients and graft survival were determined.
Results: Among 590 kidney transplant recipients, 13 adult patients with PTLD were included in this study. The mean age of the patients was 42.15 (range: 25-58) years at the time of PTLD diagnosis, and 9 patients were male. Histology was distributed in 9 diffuse large B cell, 1 Malt lymphoma, 1 Burkitt lymphoma, 2 Hodgkin-like PTLD. The response rate to rapamycin alone was 30.8%. The mean overall survival period was 23.38 months and 11 patients are still alive. In total, 10 patients (76.9%) achieved a complete remission with functioning graft in 11 (84.6%) patients.
Conclusion: Despite the retrospective focus and limited number of patients, this study provides promising results regarding the effectiveness of stopping calcineurin inhibitors and switching to rapamycin for patients with PTLD.

 
Keyword(s): LYMPHOMA THERAPY, RAPAMYCIN, TRANSPLANT
 
 
References: 
  • Not Registered.
  •  
  •  
 
Citations: 
  • Not Registered.
 
+ Click to Cite.
APA: Copy

ASHRAFI, F., & SHAHIDI, S., & EBRAHIMI, Z., & MORTAZAVI, M. (2015). OUTCOME OF RAPAMYCIN THERAPY FOR POST- TRANSPLANT- LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION: CASE SERIES. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), 9(1), 26-32. https://www.sid.ir/en/journal/ViewPaper.aspx?id=509999



Vancouver: Copy

ASHRAFI FARZANEH, SHAHIDI SHAHRZAD, EBRAHIMI ZEINAB, MORTAZAVI MOJGAN. OUTCOME OF RAPAMYCIN THERAPY FOR POST- TRANSPLANT- LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION: CASE SERIES. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR). 2015 [cited 2021July26];9(1):26-32. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=509999



IEEE: Copy

ASHRAFI, F., SHAHIDI, S., EBRAHIMI, Z., MORTAZAVI, M., 2015. OUTCOME OF RAPAMYCIN THERAPY FOR POST- TRANSPLANT- LYMPHOPROLIFERATIVE DISORDER AFTER KIDNEY TRANSPLANTATION: CASE SERIES. INTERNATIONAL JOURNAL OF HEMATOLOGY-ONCOLOGY AND STEM CELL RESEARCH (IJHOSCR), [online] 9(1), pp.26-32. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=509999.



 
  pdf-File
Yearly Visit 35
 
 
Latest on Blog
Enter SID Blog